-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KH9ryRvO0RvRwGjr1prUSMJozLvCfFTfHvYeQF6eG32/AOYhz9/UxRuof+nTsOWQ R9aTkisjgjyCMz4VcLyVlw== 0001193125-06-019844.txt : 20060828 0001193125-06-019844.hdr.sgml : 20060828 20060203172010 ACCESSION NUMBER: 0001193125-06-019844 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20060203 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OSCIENT PHARMACEUTICALS CORP CENTRAL INDEX KEY: 0000356830 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 042297484 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 7813982300 MAIL ADDRESS: STREET 1: 1000 WINTER STREET STREET 2: SUITE 2200 CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: GENOME THERAPEUTICS CORP DATE OF NAME CHANGE: 19941215 FORMER COMPANY: FORMER CONFORMED NAME: COLLABORATIVE RESEARCH INC DATE OF NAME CHANGE: 19920703 CORRESP 1 filename1.htm ACCELERATION REQUEST

Oscient Pharmaceuticals Corporation

1000 Winter Street, Suite 2200

Waltham, MA 02451

 

February 3, 2006

 

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-6010

Attention: Jeffrey Riedler

 

 

  Re: Oscient Pharmaceuticals Corporation—Request for Acceleration of Effectiveness
       of Registration Statement on Form S-3 (File No. 333-118026)

 

Dear Mr. Riedler:

 

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Oscient Pharmaceuticals Corporation (the “Company”), hereby requests that the Company’s Post-Effective Amendment No. 6 to its Registration Statement on Form S-3 (File No. 333-118026) be declared effective at 4 p.m. Eastern Time on February 6, 2006 or as soon as possible thereafter.

 

The Company acknowledges that (i) should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing, (ii) the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing, and (iii) the Company may not assert this action as defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

 

Please call Matthew Choate of Ropes & Gray LLP at (617) 951-7153 if you have any questions. Thank you for your assistance.

 

Very truly yours,

 

OSCIENT PHARMACEUTICALS CORPORATION

By:  

/s/ Steve M. Rauscher

   

Name: Steven M. Rauscher

Title: President and Chief Executive Officer

 -----END PRIVACY-ENHANCED MESSAGE-----